Birch Grove Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Birch Grove Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-30,850	Closed	-$2.73M	–	39
2021 Q4	$2.73M	Hold	30,850	–	–	1.23%	23
2021 Q3	$2.38M	Sell	30,850 -4,500	-13%	-$355K	1.12%	27
2021 Q2	$2.95M	Hold	35,350	–	–	1.43%	23
2021 Q1	$2.67M	Buy	35,350 +2,000	+6%	+$163K	1.16%	27
2020 Q4	$2.92M	Buy	33,350 +6,700	+25%	+$531K	1.53%	19
2020 Q3	$2.03M	Buy	+26,650	New	+$2.7M	1.1%	27

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Birch Grove Capital's BMRN Position: Q1 2022 in Review

Birch Grove Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 30,850 shares — an estimated $2.73M sold.

Birch Grove Capital first reported a position in BMRN in Q3 2020 and held it in 6 quarters. The position peaked at $2.95M in Q2 2021. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Birch Grove Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Birch Grove Capital sold 30,850 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $2.73M.
Birch Grove Capital first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 6 quarters.
Birch Grove Capital's BioMarin Pharmaceuticals position peaked at $2.95M in Q2 2021.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Birch Grove Capital's 13F filing for Q1 2022, filed 17 May 2022.